NEW YORK (GenomeWeb News) – Cepheid this week updated its test pipeline with a focus on gonorrhea and chlamydia, cancer, and tuberculosis over the next few years.

Speaking at two investor conferences, Cepheid CEO John Bishop outlined his company's plans to expand its testing menu through 2017, when if all goes according to plans, the company would have a total of 42 tests available globally.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.